Dr Fu Sang Luk, PHARMD in South San Francisco, CA - Pharmacist

Dr Fu Sang Luk, PHARMD is a Pharmacist based in South San Francisco, California. Dr Fu Sang Luk is licensed to practice in California (license number 83735) and his current practice location is 550 Palm Ave, South San Francisco, California. He can be reached at his office (for appointments etc.) via phone at (415) 602-0822.

NPI number for Dr Fu Sang Luk is 1164025342 and his current mailing address is 550 Palm Ave, South San Francisco, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1164025342.

Contact Information

	Dr Fu Sang Luk, PHARMD
	550 Palm Ave, South San Francisco, CA 94080-2658
	(415) 602-0822
	Not Available

Healthcare Provider's Profile

Full Name	Dr Fu Sang Luk
Gender	Male
Speciality	Pharmacist
Location	550 Palm Ave, South San Francisco, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1164025342
Provider Enumeration Date: 11/19/2020
Last Update Date: 12/13/2020

Medical Identifiers

Medical identifiers for Dr Fu Sang Luk such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1164025342	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	83735 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Fu Sang Luk is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Fu Sang Luk, PHARMD 550 Palm Ave, South San Francisco, CA 94080-2658 Ph: (415) 602-0822	Dr Fu Sang Luk, PHARMD 550 Palm Ave, South San Francisco, CA 94080-2658 Ph: (415) 602-0822

News Archive

Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

Aquaporin-4 plays a key role in brain inflammation

A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

Pharmacist in South San Francisco, CA

Sandra Moonhee Lee, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-2627
Sara Tran, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 451 S Airport Blvd, South San Francisco, CA 94080 Phone: 650-872-0637
Esther Koeshadi, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, Kaiser Permanente Inpatient Pharmacy 3rd Floor, South San Francisco, CA 94080 Phone: 650-742-2486 Fax: 650-742-2632
Dr. Winnie Lau, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-301-4684
Ms. Cynthia Y Kwan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-758-5305
Melissa Marsinko, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-2486
Patrick K Lam, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, Inpatient Pharmacy, 3rd Flr Tower, South San Francisco, CA 94080 Phone: 650-742-2486 Fax: 650-742-2632

Dr Fu Sang Luk, PHARMD - Pharmacist in South San Francisco, CA